Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06705387 · ClinicalTrials.gov registry record · Phase 2
Dupilumab Versus Topical Corticosteroid Effectiveness - Comparison in the Treatment of Stenotic EoE
A Phase 2 study of Eosinophilic Esophagitis, sponsored by University of Colorado, Denver.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 72
- Enrollment target
- 1
- Study location
NCT06705387 is a Phase 2 study of Eosinophilic Esophagitis that is actively recruiting participants, run by University of Colorado, Denver. The registered enrollment target is 72 participants, below the 862-participant average among 44 other Eosinophilic Esophagitis trials with a reported enrollment target (92% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06705387, a Phase 2 study of Eosinophilic Esophagitis, is actively recruiting participants, sponsored by University of Colorado, Denver.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 72 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this clinical trial is to \[primary purpose: e.g., learn if intervention or health behavior can treat, prevent, diagnose etc.\] in \[describe participant population/primary condition; could include any of the following: sex/gender, age groups, healthy volunteers\]. The main question\[s\] it aims to answer \[is/are\]: Does dupilumab or swallowed topical fluticasone improve the diameter of the esophagus more? Does dupilumab or swallowed topical fluticasone reduce inflammation in the esophagus more? Are comparative effective clinical trials feasible in this patient population? Researchers will compare dupilumab 300 mg weekly compared to swallowed fluticasone to see if there is a difference in treatment response. Participants will be asked to: * Be randomized to either dupilumab sq weekly or swallowed topical fluticasone twice daily. * Participate in 8 study visits over 52 weeks * Complete questionnaires * Have an endoscopy with biopsies and EndoFLIP measurements. * Swallow an Esophageal String Test
Conditions Studied
Interventions
- BIOLOGICAL Dupilumab
- DRUG Fluticasone
Study Locations (1)
Colorado
- Children's Hospital Colorado/University of Colorado School of Medicine - Aurora
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 72 participants |
| Start Date | 2024-12-23 |
| Est. Completion | 2027-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06705387
The ClinicalTrials.gov registry entry for NCT06705387 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 72 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 862-participant average among 44 other Eosinophilic Esophagitis trials with a reported enrollment target (92% lower). The listed sponsor is University of Colorado, Denver, which has 1,283 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Eosinophilic Esophagitis appearing as the primary indexed condition, and to 2 interventions - of which Dupilumab is the first listed.
NCT06705387 reports 1 study location spanning 1 distinct geographic area - top geographies include Colorado.
Frequently Asked Questions
What is clinical trial NCT06705387 about?
NCT06705387 is a clinical study titled "Dupilumab Versus Topical Corticosteroid Effectiveness - Comparison in the Treatment of Stenotic EoE". The goal of this clinical trial is to \[primary purpose: e.g., learn if intervention or health behavior can treat, prevent, diagnose etc.\] in \[describe participant population/primary condition; could include any of the following: sex/gender, age groups, healthy volunteers\]. The main question\[s\]...
What is the current status of trial NCT06705387?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 72 participants. The study started on 2024-12-23. Estimated completion is 2027-03.
What conditions does trial NCT06705387 study?
This clinical trial studies the following conditions: Eosinophilic Esophagitis.
What interventions are being tested in trial NCT06705387?
The interventions under investigation include: Dupilumab (BIOLOGICAL), Fluticasone (DRUG).
Who is sponsoring clinical trial NCT06705387?
This trial is sponsored by University of Colorado, Denver, which has 1,283 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06705387 being conducted?
This trial has 1 study location across Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Eosinophilic Esophagitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study in Adult Participants With EoE to Evaluate Vonoprazan 20 mg Compared to Placebo After 12 Weeks and to Evaluate Vonoprazan 20 mg Up to 24 Weeks
RECRUITING · Phase 2
-
Zemaira Eosinophilic Esophagitis Pilot Study
RECRUITING · Phase 2
-
Efficacy and Safety Study of Reslizumab to Treat Eosinophilic Esophagitis in Subjects Aged 5 to 18 Years
COMPLETED · Phase 2
-
A Study of Flovent in Patients With Eosinophilic Esophagitis
COMPLETED · Phase 2
-
Dose Ranging Study of RPC4046 in Eosinophilic Esophagitis
COMPLETED · Phase 2
-
Efficacy and Safety of QAX576 in Patients With Eosinophilic Esophagitis
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.